Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Probiotic formula settles well

This article was originally published in The Tan Sheet

Executive Summary

Results of Nestle-sponsored research show an experimental infant formula containing a probiotic was as "safe and well-tolerated" as the control formula provided for seven months to infants who were not breast fed after each was 14 days old. The 55 infants in the control group and the 42 in the experimental group showed equivalence in mean weight gain and no statistically significant differences in recumbent length, head circumference or incidence of adverse events, according to Giuseppe Puccio, M.D., of the University of Palermo's Neonatology Institute of Obstetrics, Italy, et al. Additionally, infants in the probiotic group had fewer constipation problems and "had stool characteristics that suggest that the experimental formula was tolerated well," the researchers say. The study was conducted to determine whether the establishment of an intestinal microbiota in the gastrointestinal tract can come from using formula with a probiotic similar to the bifidobacteria created by non-digestible oligosaccharides in human breast milk. The control formula was Nestle's Nan starter formula and the experimental formula was Nan plus units of BL999 probiotic and a mixture of 90% galacto- and 10% fructo-oligosaccharides, according to the study published in the January issue of Nutrition...

You may also be interested in...



Research & Development In Brief

Nestle eyes infant probiotic products: Nestle Nutrition is looking to launch probiotic-containing infant nutrition products targeting upper respiratory tract infections, according to an agreement announced March 28. New Zealand biotech firm BLIS Technologies has agreed to work exclusively with the Nestle SA division to carry out the research and development of probiotics "suitable for incorporation into infant nutrition products," the company says. "If the project proceeds according to plan, the company will commit significant resources to the development over the next three years," BLIS says. The probiotic helps provide protection against Streptococcus pyogenes, BLIS says, adding that the agreement should enable it to "build a platform of probiotics with significant market opportunities." This is not Nestle's first foray into infant probiotics (1"The Tan Sheet" Jan. 29, 2007, In Brief)...

US High Court Punts On ‘Objective Falsity’ FCA Standard

Can a false-claims suit be filed if doctors have different opinions about whether a treatment was necessary? The Supreme Court won’t say.

Warning Letter Close-Outs – February 2021

No device-related close-out letters were released by the US FDA last month.

Topics

UsernamePublicRestriction

Register

OM004078

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel